RE: Takeover Target29 Sep 2023 09:00
Added some more ! More buys than sells?
Knicked from advfn Paul Hill PMH Capital ltd :
'Unlike the consumer world, commercialising break-through medical science can often be frustratingly slow, even for major innovations. Why?
Well simplistically, there's a natural inertia built into the healthcare system. Here doctors are inherently cautious and need time to familiarise themselves with & fully deploy the latest technology. Equally, US insurers & public bodies (Medicare & Medicaid) must also agree to pick up the costs. That is (hopefully) before the hockey-stick growth begins & the product ultimately becomes the industry's de facto standard.
Unfortunately however both of these factors have impacted the initial pace of adoption of Verici Dx’s best-of-breed kidney transplant diagnostic Tutivia. Consequently at today’s interims, management reduced their near term revenue projections, but reiterated that #VRCI’s mid 2024 cash runway should be unaffected thanks to higher research revenues.
Moreover, Tutivia test volumes are now accelerating, albeit from low levels, as more transplant centres come on stream. While, the company also expects to receive full Medicare reimbursement (re under Local Cover Determination) by Q1’24, which should similarly boost turnover.
On the R&D front, significant progress is being made here as well. With its unique pre-transplant diagnostic Clarava on track for commercial launch in Q4'23. Elsewhere, initial sales of its 3rd test Protega are slated for 2025, which aims to predict the risk of kidney fibrosis and long-term graft failure.
CEO Sara Barrington commenting: "The clinician response to our 1st product, Tutivia, following its commercial launch in Jan’23 clearly demonstrates how much they value the key benefits and recognise the strong differentiating features. We are also excited to have announced a 2nd successful product, Clarava following the recently completed clinical validation study showing excellent results. We also completed enrolment for the validation study on our 3rd product, Protega - which completes the end-to-end testing for the portfolio as we look ahead."
"Although the timing effects on early adoption are frustrating, we have been able to make savings in other areas and are focused on research collaborations to help build a solid platform for future growth. At the same time, we are continuing to deliver on our strategy of transforming kidney transplant patient outcomes, as we move further into commercialisation”.
So what does all this mean?
Well top level, given Tutivia's “outstanding clinician feedback” - I’m highly confident Verici Dx's suite of cutting edge kidney transplant diagnostics will eventually become a major success. Likewise providing the Board with several attractive options (both internal & external) to finance its growth trajectory for years ahead.'
GL.
Sign In
Follow the stocks
